InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a report issued on Sunday. The firm set a “sell” rating on the stock.

InspireMD Price Performance

Shares of NSPR opened at $2.72 on Friday. InspireMD has a one year low of $1.81 and a one year high of $3.85. The company’s fifty day moving average price is $2.76 and its 200 day moving average price is $2.51. The company has a market capitalization of $67.90 million, a PE ratio of -3.58 and a beta of 0.90.

InspireMD (NYSE:NSPR) last announced its earnings results on Tuesday, August 6th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The business had revenue of $1.74 million for the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. During the same quarter in the previous year, the company earned ($0.24) EPS. Analysts anticipate that InspireMD will post -0.82 earnings per share for the current year.

Institutional Trading of InspireMD

A hedge fund recently bought a new stake in InspireMD stock. Mesirow Financial Investment Management Inc. purchased a new position in shares of InspireMD, Inc. (NYSE:NSPR) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 30,000 shares of the company’s stock, valued at approximately $71,000. Mesirow Financial Investment Management Inc. owned approximately 0.13% of InspireMD at the end of the most recent reporting period. Hedge funds and other institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.